Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-032 in Healthy Adults and Adults with Cystic Fibrosis
NCT05712538Phase 1Completed
- Sponsor
- Arcturus Therapeutics
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ARCT-032 in cystic fibrosis (CF) (3 arms), sponsored by Arcturus Therapeutics. Primary endpoint: Incidence, severity and dose-relationship of Adverse Events at 4 weeks. Started Feb 2023; status: completed.
02
Drugs
ARCT-032
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05712538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712538.